Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Catis Inc. (140430:KRX), powered by AI.
Catis Inc. is currently trading at ₩828. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Catis Inc. on Alpha Lenz.
Catis Inc.'s P/E ratio is -7.5.
“Catis Inc. trades at a P/E of -7.5 (undervalued) with modest ROE of -19.2%. 3Y revenue CAGR of 13.9% highlights clear growth momentum.”
Ask for details →Catis Inc., a prominent player in the bio-pharmaceutical industry, specializes in the development and commercialization of innovative therapeutic solutions aimed at addressing unmet medical needs. With a focus on advancing treatment options, Catis Inc. invests heavily in research and development to create cutting-edge drugs and technologies that have the potential to revolutionize patient care. The company's product pipeline includes a variety of treatments targeting chronic diseases, rare disorders, and life-threatening conditions, making significant strides in oncology and neurology. Catis Inc. plays a vital role in the healthcare sector, contributing to critical improvements in medical research and patient outcomes. Its partnerships with major healthcare institutions and research organizations enable it to leverage collaborative efforts and expand its impact across the pharmaceutical landscape. Additionally, Catis Inc. is involved in large-scale production and distribution networks, ensuring that its products are accessible to a global patient base. With its commitment to innovation and excellence, Catis Inc. stands out as a key entity in advancing medical science and providing essential healthcare solutions.
“Catis Inc. trades at a P/E of -7.5 (undervalued) with modest ROE of -19.2%. 3Y revenue CAGR of 13.9% highlights clear growth momentum.”
Ask for details →Catis Inc. (ticker: 140430) is a company listed on KRX in the Industrials sector (Building Products & Equipment). Market cap is $15.8B.
The current price is ₩828 with a P/E ratio of -7.48x and P/B of 1.15x.
ROE is -19.15% and operating margin is 5.03%. Annual revenue is $31.7B.